Abstract
The global emergence of Streptococcus pneumoniae resistance to fluoroquinolones is alarming and has grown to be a cause for significant concern worldwide. We report the first three cases of levofloxacin resistant S. pneumoniae isolates in a tertiary medical center in Beirut, Lebanon. Judicious use of antimicrobial agents is imperative to limit the spread of such resistant strains.
Copyright © 2010 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.
MeSH terms
-
Aged
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use*
-
Cefepime
-
Ceftazidime / pharmacology
-
Ceftazidime / therapeutic use
-
Cephalosporins / pharmacology
-
Cephalosporins / therapeutic use
-
Clarithromycin / pharmacology
-
Clarithromycin / therapeutic use
-
Drug Resistance, Multiple, Bacterial*
-
Humans
-
Imipenem / pharmacology
-
Imipenem / therapeutic use
-
Lebanon
-
Levofloxacin*
-
Male
-
Ofloxacin / pharmacology*
-
Ofloxacin / therapeutic use*
-
Pneumococcal Infections / drug therapy*
-
Pneumococcal Infections / microbiology
-
Pneumonia, Pneumococcal / drug therapy*
-
Pneumonia, Pneumococcal / microbiology
-
Streptococcus pneumoniae / drug effects*
-
Vancomycin / pharmacology
-
Vancomycin / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
Levofloxacin
-
Vancomycin
-
Imipenem
-
Cefepime
-
Ceftazidime
-
Ofloxacin
-
Clarithromycin